厦门艾德生物医药科技股份有限公司 2024 年度监事会工作报告 厦门艾德生物医药科技股份有限公司（以下简称"公司"）监事会严格依据 《公司法》《证券法》等法律法规及《公司章程》的规定，按照《监事会议事规 则》的要求，切实履行监督职责，对公司的生产经营、董事及高级管理人员履职 等情况进行监督，有效维护了公司和全体股东的合法权益。现将2024年度监事会 主要工作情况报告如下： 一、监事会会议召开情况 2024年度，公司共召开8次监事会会议，会议的召集、召开程序均符合《公 司法》《公司章程》及《监事会议事规则》的规定，并对相关议案进行了认真审 议。具体会议情况如下： （四）公司对外担保情况 | 会议时间 | 会议届次 | 会议主要内容 | | --- | --- | --- | | 2024年2月 | 第三届监事会 | 审议通过《关于豁免公司第三届监事会第十五次会议通知期 | | 7日 | 第十五次会议 | 限的议案》《关于以集中竞价交易方式回购公司股份的议案》 | | 2024年4月 | 第三届监事会 | 审议通过《2023年度监事会工作报告》《2023年度财务决算报 | | 13日 | 第十六次会议 | 告》《 ...

厦门艾德生物医药科技股份有限公司 董事会关于独立董事独立性评估的专项意见 董 事 会 厦门艾德生物医药科技股份有限公司（以下简称"公司"）董事会根据《上 市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关法律法 规、规章制度的规定，并结合公司现任独立董事王恩华先生、沈哲先生、吴乔女 士出具的《独立董事独立性自查情况表》，就公司现任独立董事的独立性情况进 行评估并出具如下专项意见： 2025 年 4 月 22 日 经核查，公司现任独立董事王恩华先生、沈哲先生、吴乔女士均未在公司担 任独立董事以外的任何职务，也未在公司主要股东担任任何职务，与公司及公司 主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存 在影响独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上 市公司自律监管指引第2号——创业板上市公司规范运作》等法律法规、规范性 文件及《公司章程》中关于独立董事的独立性要求。 厦门艾德生物医药科技股份有限公司 ...

一、使用闲置自有资金进行现金管理的情况 证券代码：300685 证券简称：艾德生物 公告编号：2025-021 厦门艾德生物医药科技股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"）于 2025年4月19日召开的第四届董事会第六次会议和第四届监事会第五次会议，分 别审议通过《关于使用闲置自有资金进行现金管理的议案》，同意公司（含控股 子公司，下同）使用不超过人民币15亿元的闲置自有资金进行现金管理，期限为 自2025年8月17日起12个月，该议案尚需提交公司股东大会审议批准。在上述额 度及决议有效期内，可循环滚动使用，授权公司经营管理层行使该项资金管理决 策权，并由公司财务部负责具体办理相关事宜。现将具体情况公告如下： 1、投资目的 为提高公司资金使用效率，在保证日常生产经营资金需求、有效控制投资风 险的情况下，充分利用闲置自有资金购买安全性较高、流动性好的中低风险或稳 健性的投资产品，增加资金收益，为公司及股东获得更多回报。 2、投资品种 公 ...

计提长期股权投资减值损失的原因说明：经核查，公司投资的参股公司 Universal Sequencing Technology Corporation 出现减值迹象，基于谨慎性原则，公 司按照会计准则相关规定，对该笔长期股权投资计提减值损失 822.88 万元。 证券代码：300685 证券简称：艾德生物 公告编号：2025-025 厦门艾德生物医药科技股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本年度计提减值准备的情况概述 根据《企业会计准则》及公司会计政策等相关规定，基于谨慎性原则，公司 对合并财务报表范围内截至 2024 年 12 月 31 日的应收票据、应收账款、其他应 收款、长期应收款、长期股权投资等资产进行了减值测试，判断存在可能发生减 值的迹象，因此计提相应的资产减值准备。本年度计提资产减值准备的资产范围 和金额如下： | 项目 | 金额（元） | | | --- | --- | --- | | 1、信用减值损失 | | 30,218,314.54 | | 应收票据坏账损失 | | ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-027 厦门艾德生物医药科技股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东大会届次：2024年度股东大会 2．股东大会的召集人：厦门艾德生物医药科技股份有限公司（以下简称"公 司"或"艾德生物"）董事会 （1）现场投票：股东本人出席现场会议或通过授权委托他人出席现场会议； （2）网络投票：本次股东大会将通过深圳证券交易所交易系统和互联网投 票系统向公司股东提供网络形式的投票平台，公司股东可以在上述网络投票时间 内通过上述系统行使表决权。 公司股东只能选择现场投票和网络投票中的一种表决方式，表决结果以第一 次有效投票结果为准。 6．股权登记日：2025年5月7日（星期三） 3．会议召开的合法、合规性： 经公司第四届董事会第六次会议审议通过，决定召开2024年度股东大会。召 集程序符合有关法律、法规、部门规章、规范性文件和《公司章程》的规定。 4．会议召开的日期、时间： （1）现场会议召开时间为：2025年5月14 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-018 厦门艾德生物医药科技股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届监事会第五次会议于2025年4月19日在厦门市海沧区鼎山路39号公司会议 室以通讯和现场表决相结合的方式召开，会议应到监事3人，实到监事3人，符合 公司章程规定的法定人数。本次会议通知于2025年4月9日以电子邮件等形式发出， 会议的通知和召开符合《公司法》与《公司章程》的规定。本次会议由公司监事 会主席涂东明先生主持。 公司2024年度财务报告已经立信会计师事务所（特殊普通合伙）审计。公司 2024年实现营业收入1,108,948,700.11元，实现归属于上市公司股东的净利润 254,863,444.95元。 二、监事会会议审议情况 1、审议通过《2024年度监事会工作报告》 表决结果：3票赞成，0票反对，0票弃权，本议案获表决通过。 根据2024年监事会的工作情况，监事会起草 ...

证券代码：300685 证券简称：艾德生物 公告编号：2025-017 厦门艾德生物医药科技股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第四届董事会第六次会议于2025年4月19日在厦门市海沧区鼎山路39号公司会议 室以通讯和现场表决相结合的方式召开，会议应到董事7人，实到董事7人，符合 公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次会议 通知于2025年4月9日以电子邮件等形式发出，会议的通知和召开符合《公司法》 与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先生主持。 二、董事会会议审议情况 1、审议通过《2024年度总经理工作报告》 表决结果：7票赞成，0票反对，0票弃权，本议案获表决通过。 董事会听取了公司总经理所作的《2024年度总经理工作报告》，认为2024年 度公司经营管理层有效执行了董事会、股东大会的各项决议。 详细内容请见公司与本公告同日刊登在中国证监会指定的创业 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,108,948,700.11, representing a 6.27% increase compared to CNY 1,043,506,694.32 in 2023[16] - The net profit attributable to shareholders for 2024 was CNY 254,863,444.95, a decrease of 2.53% from CNY 261,484,433.37 in 2023[16] - The net profit after deducting non-recurring gains and losses was CNY 233,087,950.27, down 2.45% from CNY 238,952,550.49 in the previous year[16] - The net cash flow from operating activities increased by 14.44% to CNY 341,845,598.08, compared to CNY 298,715,870.41 in 2023[16] - The total assets at the end of 2024 were CNY 2,064,801,711.06, reflecting a 6.71% increase from CNY 1,934,881,553.02 at the end of 2023[16] - The net assets attributable to shareholders increased by 8.22% to CNY 1,843,264,757.86, compared to CNY 1,703,320,906.08 in 2023[16] - The basic earnings per share for 2024 were CNY 0.64, a decrease of 3.03% from CNY 0.66 in 2023[16] - The company reported a total non-operating income of approximately $21.78 million, a decrease from $22.53 million in 2023, and significantly lower than $106.76 million in 2022[22] - The company achieved a revenue of 776.71 million CNY in the domestic market for 2024, earning the title of "National Manufacturing Single Champion" [62] - The revenue from drug clinical research services surged by 81.38% year-on-year, amounting to ¥160,896,610.26, up from ¥88,706,635.50 in 2023[66] - Domestic sales slightly decreased by 1.08% to ¥776,706,105.56, while international sales increased by 28.61% to ¥332,242,594.55[69] - The gross profit margin for the in vitro diagnostic industry was 84.75%, reflecting a year-on-year increase of 0.78%[70] R&D and Innovation - R&D investment reached 216.11 million yuan, accounting for 19.49% of revenue, with a year-on-year growth of 6.35%[53] - The company holds 32 Class III medical device registrations and 68 patents, including 62 invention patents, demonstrating its strong innovation capabilities[53] - The company has developed a comprehensive R&D team of 523 members, focusing on various disciplines to drive efficient project management and innovation[53] - The company is actively involved in research and development, aiming to innovate new products and technologies[126] - The company has completed the development of multiple gene testing kits, enhancing its product line and core competitiveness[81] - The company has launched a new high-throughput gene sequencing instrument, ADx-SEQ200 Plus, which offers a cost-effective solution compared to imported brands[38] - The company has introduced a real-time fluorescence quantitative PCR analyzer, GEMINI, which doubles throughput and simplifies operations for tumor precision diagnostics[38] - The company has developed and received approval for 32 tumor gene detection products, making it a leading enterprise in the industry with the most comprehensive product range[32] Market and Strategic Focus - The company’s strategic focus on precision medicine aligns with the growing demand for tumor gene testing, which has expanded from drug guidance to comprehensive patient lifecycle management[25] - The global cancer incidence is approximately 20 million new cases annually, with China accounting for over 4.8 million new cases, representing about 24% of the global total[26] - The proportion of targeted and immunotherapy drugs in the global oncology drug development pipeline has exceeded 50%, driving rapid growth in related gene testing demand[27] - The company has formed strategic partnerships with over 100 international distributors, enhancing its global operational network [63] - The company has established a direct sales network covering over 500 top hospitals in China, supported by a professional team of nearly 400 people [57] - The company has successfully registered three Class III (CDx) products in overseas markets, including the ROS1 Gene Fusions Detection Kit and the AmoyDx® Pan Lung Cancer Gene PCR panel, which are covered by health insurance in Japan and South Korea[41] Regulatory and Compliance - The regulatory environment is increasingly emphasizing compliance, which is expected to elevate industry standards and concentration, benefiting the company[29] - The company emphasizes strict production and quality control processes, ensuring compliance with regulatory standards and maintaining product quality[48] - The company has established a policy monitoring mechanism to respond to potential regulatory risks[105] - The company has established a comprehensive internal control system, ensuring the legality and compliance of operations, with no significant defects found in financial reporting controls during the reporting period[166] Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal regulations and the company's articles of association[115] - The company has established specialized committees under the board of directors, including the audit committee and the strategic development committee, to enhance governance effectiveness[114] - The company has a performance evaluation and incentive mechanism that aligns with its development status, ensuring transparency in the hiring and assessment of senior management[116] - The company has experienced changes in its board and management personnel, indicating a shift in governance and operational strategy[122] - The company’s independent directors bring significant academic and industry experience, contributing to its governance[128][129][130] Employee and Training Development - The total number of employees at the end of the reporting period is 1,144, including 683 at the parent company and 461 at major subsidiaries[155] - The professional composition includes 523 technical personnel, 371 sales personnel, and 111 production personnel, among others[156] - The educational background of employees shows 25 with a doctorate, 251 with a master's degree, and 868 with a bachelor's degree or below[156] - The company emphasizes employee development through a structured training system and a scientific incentive mechanism, fostering a positive work environment[175] - The company has actively integrated high-quality training resources to enhance employee skills and overall team capabilities, supporting sustainable development[158] Environmental and Social Responsibility - The company adheres to environmental protection laws and has established a comprehensive environmental management system, focusing on low-carbon and sustainable development[172] - The company actively engages in public welfare activities related to cancer prevention and awareness, contributing to early screening and diagnosis efforts[175] - The company integrates environmental considerations throughout the project lifecycle, aligning with national carbon neutrality goals[175] - The company has not reported any administrative penalties related to environmental issues during the reporting period[172] Cash Dividend and Profit Distribution - The company maintained a cash dividend policy with a total cash dividend amount of ¥117,918,590.70, which represents 100% of the total profit distribution[161] - For the 2024 profit distribution plan, the company proposed a cash dividend of ¥3 per 10 shares (including tax), with no stock dividends or capital reserve transfers[163] - The company’s profit distribution policy has remained unchanged during the reporting period, ensuring clarity and completeness in decision-making processes[161] - The company has implemented a reasonable profit distribution and cash dividend policy, ensuring the protection of investor rights and interests[175] Financial Management and Audit - The company has engaged Lixin Accounting Firm for auditing services, with a fee of 1 million yuan and a continuous service period of 10 years[183] - The company has appointed Lixin Accounting Firm as the internal control auditing firm, with an internal control audit fee of 200,000 yuan[184] - The internal control evaluation report indicates that all evaluated units accounted for 100% of the company's total assets and revenue[168] - The company has committed to strengthen internal controls and improve management levels to ensure normal operations and reduce management risks[179]

Financial Performance - The company's revenue for Q1 2025 was ¥272,090,793.91, representing a 16.63% increase compared to ¥233,288,808.06 in the same period last year[5] - Net profit attributable to shareholders was ¥90,471,778.52, a 40.92% increase from ¥64,199,068.03 year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥87,223,537.32, up 53.07% from ¥56,981,941.60 in the previous year[5] - Basic and diluted earnings per share were both ¥0.23, a 43.75% increase from ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥272,090,793.91, an increase of 16.6% compared to ¥233,288,808.06 in the previous period[20] - Net profit for the current period was ¥90,471,778.52, representing a significant increase of 40.9% from ¥64,199,068.03 in the previous period[21] - The company's profit before tax was ¥101,793,500.12, an increase of 38.3% from ¥73,566,224.34 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was ¥103,254,852.84, reflecting a 28.14% increase compared to ¥80,577,903.10 in the same period last year[5] - Operating cash flow increased to 103,254,852.84 from 80,577,903.10, a rise of 28.06%[22] - Total cash inflow from operating activities reached 290,859,140.41, compared to 273,690,053.97 in the previous period, marking a 6.25% increase[22] - Cash and cash equivalents at the end of the period decreased to 288,933,634.09 from 323,750,184.55, a drop of 10.76%[23] - The company reported a net increase in cash and cash equivalents of -26,528,201.73, contrasting with a net increase of 122,672,317.88 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,163,512,829.30, a 4.78% increase from ¥2,064,801,711.06 at the end of the previous year[5] - Total liabilities rose to ¥244,665,855.76, compared to ¥221,536,953.20, indicating an increase of 10.4%[18] - The company's total assets increased to ¥2,163,512,829.30 from ¥2,064,801,711.06, marking a growth of 4.8%[18] - Total current assets increased to ¥1,891,421,886.64 from ¥1,788,399,896.77[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,012[12] - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.31% of shares, totaling 87,701,616 shares[12] - The total number of shares held by the top ten unrestricted shareholders is 87,701,616, with Forward Investment (Hong Kong) Limited being the largest[13] - The total number of restricted shares at the end of the period is 3,464,606, down from 3,527,230 due to the unlocking of shares[14] - The company has no reported related party relationships or concerted actions among the top shareholders[13] Expenses and Investments - Total operating costs amounted to ¥171,878,070.83, up from ¥167,788,210.58, reflecting a growth of 1.3%[20] - Research and development expenses were ¥41,536,126.88, a decrease of 14.1% from ¥48,363,080.43 in the previous period[20] - The company has a long-term investment of ¥10,497,291.81, down from ¥11,951,810.18[16] - The financial expenses showed a significant improvement, with a net income of -¥10,374,808.85 compared to -¥3,263,353.11 previously[20] Future Plans and Accounting Changes - The company plans to continue its market expansion and product development strategies, although specific details were not disclosed in the provided content[15] - The company plans to adopt new accounting standards starting in 2025, which may impact future financial reporting[24] - The first quarter report was not audited, indicating a preliminary assessment of financial performance[24]

证券代码：300685 证券简称：艾德生物 公告编号：2025-019 厦门艾德生物医药科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 以未来实施 2024 年度权益分配方案时股权登记日的总股本（扣除回购专用证券账 户股份）为基数，向全体股东每 10 股派发现金红利 3 元（含税），预计共派发现金红利 117,918,590.701元（含税），不送红股，不以资本公积金转增股本。 一、审议程序 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于 2025 年 4 月 19 日召开第四届董事会第六次会议及第四届监事会第五次会议， 审议通过了《关于 2024 年度利润分配方案的议案》。本议案尚需提交公司 2024 年度股东大会审议。 二、利润分配方案的基本情况 1、本次利润分配为公司 2024 年度利润分配。 2、根据《公司法》和《公司章程》的有关规定，2024 年提取法定盈余公积 金 21,265,143.33 元。经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 ...